A Phase I and Biodistribution Study of Ifabotuzumab, a Humanized Agonistic EphA3-Targeted Antibody, in Patients with Recurrent Glioblastoma.

Gan HK, Cher L, Inglis PL, Lwin Z, Gunjur A, Balasubramanian A, Schmidt A, Wichmann CW, Guo N, Lee ST, Thomas P, Scott FE, Shard C, Fluck K, Coombs N, Palmer J, Vail ME, Allen S, Patil A, Pal B, O'Keefe GJ, Gong SJ, Ninatti G, Day BW, Gomez GA, Janes PW, Scott AM

Open source

DOI: 10.1158/1078-0432.ccr-25-3608
Published: 2026 Sep 1
Container: Clinical cancer research : an official journal of the American Association for Cancer Research
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-25-3608,
  title = {A Phase I and Biodistribution Study of Ifabotuzumab, a Humanized Agonistic EphA3-Targeted Antibody, in Patients with Recurrent Glioblastoma.},
  author = {Gan HK and Cher L and Inglis PL and Lwin Z and Gunjur A and Balasubramanian A and Schmidt A and Wichmann CW and Guo N and Lee ST and Thomas P and Scott FE and Shard C and Fluck K and Coombs N and Palmer J and Vail ME and Allen S and Patil A and Pal B and O'Keefe GJ and Gong SJ and Ninatti G and Day BW and Gomez GA and Janes PW and Scott AM},
  year = {2026},
  journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
  doi = {10.1158/1078-0432.ccr-25-3608},
  url = {https://doi.org/10.1158/1078-0432.ccr-25-3608}
}

RIS

TY  - JOUR
TI  - A Phase I and Biodistribution Study of Ifabotuzumab, a Humanized Agonistic EphA3-Targeted Antibody, in Patients with Recurrent Glioblastoma.
AU  - Gan HK
AU  - Cher L
AU  - Inglis PL
AU  - Lwin Z
AU  - Gunjur A
AU  - Balasubramanian A
AU  - Schmidt A
AU  - Wichmann CW
AU  - Guo N
AU  - Lee ST
AU  - Thomas P
AU  - Scott FE
AU  - Shard C
AU  - Fluck K
AU  - Coombs N
AU  - Palmer J
AU  - Vail ME
AU  - Allen S
AU  - Patil A
AU  - Pal B
AU  - O'Keefe GJ
AU  - Gong SJ
AU  - Ninatti G
AU  - Day BW
AU  - Gomez GA
AU  - Janes PW
AU  - Scott AM
PY  - 2026
JO  - Clinical cancer research : an official journal of the American Association for Cancer Research
DO  - 10.1158/1078-0432.ccr-25-3608
UR  - https://doi.org/10.1158/1078-0432.ccr-25-3608
ER  -

APA

HK, G., L, C., PL, I., Z, L., A, G., A, B., A, S., CW, W., N, G., ST, L., P, T., FE, S., C, S., K, F., N, C., J, P., ME, V., S, A., A, P., B, P., GJ, O., SJ, G., G, N., BW, D., GA, G., PW, J., & AM, S. (2026). A Phase I and Biodistribution Study of Ifabotuzumab, a Humanized Agonistic EphA3-Targeted Antibody, in Patients with Recurrent Glioblastoma.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-25-3608

Source records

pubmed · retrieved 2026-09-26T03:11:54.233Z